Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Timely Immunization Subverts the Development of Peripheral Nonresponsiveness and Suppresses Tumor Development in Simian Virus 40 Tumor Antigen-Transgenic Mice

Xuehai Ye, James McCarrick, Lorraine Jewett and Barbara B. Knowles
Proceedings of the National Academy of Sciences of the United States of America
Vol. 91, No. 9 (Apr. 26, 1994), pp. 3916-3920
Stable URL: http://www.jstor.org/stable/2364562
Page Count: 5
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Timely Immunization Subverts the Development of Peripheral Nonresponsiveness and Suppresses Tumor Development in Simian Virus 40 Tumor Antigen-Transgenic Mice
Preview not available

Abstract

Tolerance to tumor cell-expressed molecules and selection of cells that evade immune surveillance during tumor progression create effective barriers to immunotherapy. We investigated the cytotoxic T-lymphocyte response to simian virus 40 (SV40) tumor (T/t) antigen in two lineages of transgenic mice bearing the same rat insulin promoter-SV40 T/t antigen (RIP Tag) hybrid gene. RIP1-Tag2 mice, which express Tag as embryos, are tolerant to Tag, whereas RIP1-Tag4 mice, which express the transgene in pancreatic islet β cells several weeks after birth and develop insulinomas, can be immunized to generate active Tag-specific cytotoxic T lymphocytes as determined by in vitro assays. Indeed, RIP1-Tag4 mice immunized with Tag by SV40 infection prior to the time of endogenous transgene expression also mount an effective in vivo cellular immune response to the Tag-expressing pancreatic β cells, and Tag-induced tumor growth is significantly delayed (up to 1 year). However, after the transgene is expressed, RIP1-Tag4 mice are unable to mount a tumor-inhibiting response upon immunization, although Tag-specific cytotoxic T cells can still be demonstrated in vitro. Our data suggest that Tag-specific T cells are rendered unresponsive in vivo in RIP1-Tag4 mice and that the establishment of this unresponsiveness to Tag can be prevented by SV40 immunization only before the onset of the transgene expression. In the older, successfully immunized mouse, decreased immune surveillance and selection of cells with down-regulation of major histocompatibility complex class I expression most likely set the stage for insulinoma development.

Page Thumbnails

  • Thumbnail: Page 
3916
    3916
  • Thumbnail: Page 
3917
    3917
  • Thumbnail: Page 
3918
    3918
  • Thumbnail: Page 
3919
    3919
  • Thumbnail: Page 
3920
    3920